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azepines with appropriate doses of short-acting or 
intermediate-acting benzodiazepines or zolpidem and to
reduce the number of potentially associated fractures in
a population of elderly New Mexico Medicaid recipients.
METHODS: The New Mexico Medicaid fee-for-service
prescription claims database was reviewed to identify
patients 65 years and older with 2 or more claims for
long-acting benzodiazepines between October 1 and
December 31, 2000. Educational letters, response forms
and prescription proﬁles were mailed to the prescribers,
pharmacies and consultant pharmacists of these patients.
The database was reviewed from March 1 to May 31,
2001 to assess changes in prescribing patterns. Based on
a previous epidemiologic study and Medicare reimburse-
ment for hip fractures, a cost analysis was performed.
RESULTS: A total of 182 patients were included in the
intervention. Educational materials were mailed to 147
prescribers, 94 pharmacies and 12 consultant pharmacists
for these patients on January 31, 2001. Sixty-four pre-
scribers (44%), 30 pharmacies (32%) and 3 consultant
pharmacists (25%) responded for 103 (57%) patients.
Overall, 16% (n = 29) of the remaining eligible patients
were no longer receiving long-acting benzodiazepine
therapy in the 3-month post-intervention period. Based
on a previous epidemiologic study, 3 fractures were
potentially prevented resulting in a cost savings of
$24,256 to Medicaid/Medicare over a period of nine
years.
CONCLUSIONS: A change in patients’ therapy and 
a potential cost savings to the Medicaid/Medicare 
programs was observed after the intervention.
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OBJECTIVES: Between 1994 and 1999, the Food and
Drug Administration approved three new antipsychotic
medications for the treatment of schizophrenia. This
study tracks antipsychotic prescription patterns in the
Department of Veterans Affairs to determine how these
new drugs have diffused in a national healthcare system.
METHODS: Pharmacy claims data were collected for all
patients with a diagnosis of schizophrenia in the Depart-
ment of Veterans Affairs (VA). Patients who were stable
on a pharmacotherapy regimen were followed over ﬁscal
year 2000 to determine how often patients switch to
another drug, how much time elapses before they switch,
the drug to which they switch, and whether they subse-
quently switch back.
RESULTS: Of the 21,873 patients with schizophrenia
who were stable for three months on their medication,
5,426 (24.8%) switched medications during the next 
year. However, half of these patients (2,708 or 49.9%)
switched back to their original therapy, usually within 30
days. Patients stable on clozapine were the least likely 
to switch (17.8%), while patients stable on quetiapine
were the most likely to switch (37.4%). When patients
switched medications, they were most likely to switch 
to olanzapine (35.1%) and least likely to switch to 
clozapine (0.7%) or quetiapine (14.0%).
CONCLUSIONS: Pharmacotherapy for schizophrenia is
a dynamic process. One quarter of patients who are stable
on an antipsychotic drug regimen change their medica-
tion within one year. Quetiapine was the least favored of
the newer drugs. Our results suggest that it is important
that all of these medications are included on formularies.
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The California Medicaid program added olanzapine 
and risperidone to its formulary in October 1997. This
resulted in an immediate but temporary increase in the
total number of patients initiating episodes of therapy
(access effect) and the substitution of second-generation
antipsychotics for older drugs.
OBJECTIVE: Model how the formulary expansion
altered drug selection decisions and then use these models
to match patients for the purpose of estimating the 
cost impact of the formulary expansion. STUDY 
POPULATION: 19,221 olanzapine, 25,252 risperidone
and 1,22,547 patient episodes using traditional drugs
were classiﬁed into three groups: patients with no previ-
ous antipsychotic use (new), patients re-starting drug
therapy and patients switching between antipsychotic
medications without a break in therapy.
METHODS: Multinomial logistic regression models of
the drug selection process were estimated then used to 
calculate propensity scores for olanzapine and risperidone
use using the post-expansion clinical decision criteria.
Health care costs were then compared within quintile bins
for these 3 treatment episode types.
RESULTS: The formulary expansion signiﬁcantly
improved access for minorities, women and urban 
residents. However, the propensity-score matching of
olanzapine and risperidone patients with patients using
traditional antipsychotics (quintile bins) did not result in
highly congruent patient populations. Patients using 
traditional antipsychotics consistently exhibited higher
levels of health care use prior to the start of the treatment
episode. Simple within-bin comparisons of health care
costs found lower costs for olanzapine and risperidone
patients. Differences based on multivariate cost models
within each quintile bin greatly reduced these differences.
However, continuous days of therapy were consistently
higher for risperidone and olanzapine patients.
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CONCLUSIONS: Patients with schizophrenia treated
with either risperidone or olanzapine achieved better drug
therapy outcomes after the formulary expansion. The
higher cost of drug therapy was largely offset by reduc-
tions in the use of other services.
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OBJECTIVES: 1) To understand why naltrexone, a med-
ication approved by the FDA to treat alcoholism, has not
diffused widely and 2) to demonstrate the use of stated
preference techniques for predicting physicians’ demand
for medications with various characteristics.
METHODS: Survey of 1372 physicians specializing in
substance abuse treatment (65% response rate). Ques-
tions about the use of naltrexone and perceptions of nal-
trexone. Stated preference questions in which physicians
are asked to select medications for treating alcoholism
based on hypothetical medication characteristics. Com-
bined actual and stated preference data are used to
examine the accuracy of stated preference data for 
forecasting demand for new medications.
RESULTS: Only 2% of physicians had never heard of 
naltrexone, 11% had heard of naltrexone but were not
conﬁdent in their knowledge about its indications. The
mean percent of alcoholism patients prescribed naltrex-
one was 13%. 37% of physicians did not prescribe nal-
trexone to any of their patients. When physicians were
asked the main reason that they did not prescribe nal-
trexone to more patients the following reasons were
given: 19% said “patients refused to take or comply with
medications;” 17% said “patients could not afford 
medications;” 11% said “small effect size relative to 
side-effects;” 10% said “patients were not in a formal
treatment program.” Other analyses will also be pre-
sented that examine ratings of efﬁcacy, side-effects, and
compliance with naltrexone relative to other more widely
used medications. Physicians demand curves and market-
share for alcoholism medications are estimated using
stated preference data.
CONCLUSIONS: Although naltrexone is familiar to
most specialists in substance abuse it is still not widely
prescribed. A variety of reasons explain why naltrexone
is not more widely prescribed. Efforts to increase its use
will require efforts focused on a number of areas, includ-
ing educating physicians and increased availability of the
medication outside of formal treatment programs.
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OBJECTIVE: Previous research evaluating labor 
market outcomes in schizophrenia has focused mainly on
patients’ earnings, providing an overall economic impact.
Two studies exploring employment participation in 
schizophrenic patients found that “negative” symptoms
(e.g., apathy and social withdrawal) are stronger predic-
tors of employment than “positive” symptoms (halluci-
nations and delusions), however, these studies were based
on a static model. In the present study, we used a dynamic
employment decision model to examine the impact of
schizophrenia symptoms on employment outcomes.
METHODS: The decision model was empirically 
estimated using patients with a DSM-III diagnosis of
schizophrenia from the Epidemiologic Catchment Area
Study data, 1980–1985 (n = 133). The variables of 
interest (presence of only positive symptoms, only nega-
tive symptoms, or both) were measured as dichotomous
variables. Ordinary least squares regression was used to
determine the effect of symptoms on months of unem-
ployment. The dependent variable was also broken into
discrete outcomes (continuous employment, discontinu-
ous employment, and unemployment) and an ordered
probit model was estimated. Both models controlled for
demographics, family social support, additional income,
and illness severity.
RESULTS: Most patients experienced both positive and
negative symptoms (82%); no patients experienced only
negative symptoms. Positive symptoms only and both
positive and negative symptoms were signiﬁcantly associ-
ated with more months of unemployment (14.2 and 13.6
months, respectively) compared with an average of 20
months in patients with no symptoms (p < 0.001); no 
difference was detected in the coefﬁcient estimates
between the positive symptoms only group and the posi-
tive and negative symptoms group. Results of the ordered
probit model were not signiﬁcant.
CONCLUSION: In this study, the presence of symptoms
in schizophrenic patients increased the duration of unem-
ployment by more than a year. This suggests that greater
symptom control, possibly through aggressive pharma-
cotherapy, may lead to increased employment rates
among schizophrenic patients, making them more 
productive members of society.
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